Worth reading
26Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
130
USD millionWording
Conditional
How definitive the wording is.This transaction
This capital increaseCounterpartyOtsuka Pharmaceutical Factory America, Inc.
Disclosing companyOtsuka Holdings Co.,Ltd.
TimelineThe spacing between the points is proportional to the actual number of days.
Target company
Manufacture of pharmaceuticals, primarily infusion products, and medical devices
Location Austin, Texas, United StatesShare capital Before capital increase: USD 0; after capital increase: USD 130 million (including capital surplus)Date of incorporation 5 February 2026
Consideration and expenses
Acquisition priceUSD 130 million (capital increase amount)
Impact on Business Performance
This transaction will have no impact on the Company's consolidated earnings forecast.
| Item | Details |
|---|---|
| Transaction name | This capital increase |
| Counterparty name | Otsuka Pharmaceutical Factory America, Inc. |
| Name of the Subject Company | Otsuka Clinical Nutrition America LLC |
| Business Description of the Subject Company | Manufacture of pharmaceuticals, primarily infusion products, and medical devices |
| Location of the Subject Company | Austin, Texas, United States |
| Capital Stock of the Subject Company | Before capital increase: USD 0; after capital increase: USD 130 million (including capital surplus) |
| Date of Establishment of the Subject Company | 5 February 2026 |
| Acquisition price | USD 130 million (capital increase amount) |
| Voting rights ownership percentage | Before 100％ (after not disclosed) |
| Impact on Business Performance | This transaction will have no impact on the Company's consolidated earnings forecast. |
| Date of board resolution | 7 May 2026 |
| Execution Date / Effective Date | June 2026 (planned) |
Items this document does not state (20)
Net Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Contract DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The capital increase in OCNA, a subsidiary of OPFA, is intended to strengthen the business base and expand the business in the United States.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.